Amundi’s Aurinia Pharmaceuticals AUPH Stock Holding History

Amundi’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$194K	Buy	+11,953	New	+$191K	﹤0.01%	1996

Other funds holding AUPH

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Amundi's AUPH Position: Q3 2026 in Review

Amundi opened a new position in Aurinia Pharmaceuticals (AUPH) in Q3 2026: 11,953 shares worth $194K. The stake represents ﹤0.01% of the portfolio and ranks #1996 among its holdings.

107 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

Amundi held 11,953 shares of Aurinia Pharmaceuticals worth $194K as of Q3 2026.
Aurinia Pharmaceuticals was a new Amundi position in Q3 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q3 2026, its #1996 holding.
107 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Amundi's 13F filing for Q3 2026, filed 6 Nov 2026.